Mortality in patients with early- or late-onset candidaemia

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 4, 2013, Pages 927-935

  De Rosa, Francesco Giuseppe ^a   Trecarichi, Enrico Maria ^b   Montrucchio, Chiara ^a   Losito, Angela Raffaella ^b   Raviolo, Stefania ^a   Posteraro, Brunella ^b   Corcione, Silvia ^a   Di Giambenedetto, Simona ^b   Fossati, Lucina ^c   Sanguinetti, Maurizio ^b   Serra, Roberto ^c   Cauda, Roberto ^b   Di Perri, Giovanni ^a   Tumbarello, Mario ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

Caspofungin; Early onset candidaemia; Healthcare associated infections; Mortality; Risk factors

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE;

ADULT; AGED; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; COHORT ANALYSIS; FATALITY; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MORTALITY; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ACADEMIC MEDICAL CENTERS; AGED; CANDIDEMIA; CROSS INFECTION; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84875240701     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks480     Document Type: Article

References (25)

1. Becksague CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal-infections in the United States, 1980-1990. J Infect Dis 1993; 167: 1247-51.
2. Edmond MB, Wallace SE, McClish DK et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239-44.
3. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-703.
4. Zaoutis TE, Argon J, Chu J et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-9.
5. Sofair AN, Lyon GM, Huie-White S et al. Epidemiology of community-onset candidemia in Connecticut and Maryland. Clin Infect Dis 2006; 43: 32-9.
6. Tumbarello M, Sanguinetti M, Trecarichi EM et al. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. J Antimicrob Chemother 2008; 62: 1379-85.
7. Bassetti M, Taramasso L, Nicco E et al. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS ONE 2011; 6: e24198.
8. Bassetti M, Trecarichi EM, Righi E et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007; 58: 325-31.
9. Leon C, Ruiz-Santana S, Saavedra P et al. Usefulness of the 'Candida score' for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37: 1624-33.
10. Shorr AF, Gupta V, Sun XW et al. Burden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large US database. Crit Care Med 2009; 37: 2519-26.
11. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-27.
12. Gulia J, Aryal S, Saadlla H et al. Healthcare-associated candidemia: a distinct entity? J Hosp Med 2010; 5: 298-301.
13. Kung HC, Wang JL, Chang SC et al. Community-onset candidemia at a university hospital, 1995-2005. J Microbiol Immunol Infect 2007; 40: 355-63.
14. Chen S, Slavin M, Nguyen Q et al. Australian Candidemia Study. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006; 12: 1508-16.
15. Friedman ND, Kaye KS, Stout JE et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann IntMed 2002; 137: 791-7.
16. Zilberberg MD, Kollef MH, Arnold H et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 2010; 10: 150.
17. Knaus WA, Wagner DP, Draper EA et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100: 1619-36.
18. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
19. Tumbarello M, Posteraro B, Trecarichi EM et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 2007; 45: 1843-50.
20. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
21. Ortega M, Marco F, Soriano A et al. Candida spp. bloodstream infection: influence of antifungal treatment on outcome. J Antimicrob Chemother 2010; 65: 562-8.
22. Reboli AC, Shorr AF, Rotstein C et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasivecandidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis 2011; 11: 261.
23. Tumbarello M, Fiori B, Trecarichi EM et al. Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. PLoS ONE 2012; 7: e33705.
24. Arnold HM, Micek ST, Shorr AF et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 2010; 30: 361-8.
25. Silva S, Negri M, Henriques M et al. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev 2012; 36: 288-305.